دورية أكاديمية
أعرض في EDS

Reasons for Discordance between 68 Ga-PSMA-PET and Magnetic Resonance Imaging in Men with Metastatic Prostate Cancer.

التفاصيل البيبلوغرافية
العنوان: Reasons for Discordance between 68 Ga-PSMA-PET and Magnetic Resonance Imaging in Men with Metastatic Prostate Cancer.
المؤلفون: Wang J; Department of Internal Medicine, New York-Presbyterian Hospital, New York, NY 10065, USA., O'Dwyer E; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA., Martinez Zuloaga J; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA., Subramanian K; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA., Hu JC; Department of Urology, Weill Cornell Medical College, New York, NY 10065, USA., Jhanwar YS; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA., Nagar H; Department of Radiation Oncology, Weill Cornell Medical College, New York, NY 10065, USA., RoyChoudhury A; Department of Population Health Sciences, Weill Cornell Medical College, New York, NY 10065, USA., Babich J; Ratio Therapeutics, Inc., Boston, MA 02210, USA., Huicochea Castellanos S; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA., Osborne JR; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA., Margolis DJA; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA.
المصدر: Cancers [Cancers (Basel)] 2024 May 29; Vol. 16 (11). Date of Electronic Publication: 2024 May 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Background: PSMA PET has emerged as a "gold standard" imaging modality for assessing prostate cancer metastases. However, it is not universally available, and this limits its impact. In contrast, whole-body MRI is much more widely available but misses more lesions. This study aims to improve the interpretation of whole-body MRI by comparing false negative scans retrospectively to PSMA PET.
Methods: This study was a retrospective sub-analysis of a prospectively collected database of patients who participated in a clinical trial of PSMA PET/MRI comparing PSMA PET and whole-body MRI from 2018-2021. Subjects whose separately read PSMA PET and MRI diagnostic reports showed discrepancies ("false negative" MRI cases) were selected for sub-analysis. The cases were reviewed by the same attending radiologist who originally read the scans. The radiologist noted specific features on MRI indicating metastatic disease that were initially missed.
Results: Of 263 cases, 38 (14%) met the inclusion criteria and were reviewed. Six classes of mpMRI false negatives were identified: anatomically normal (18, 47%), atypical MRI appearance (6, 16%), mischaracterization (1, 3%), undercall (6, 16%), obscured (4, 11%), and no abnormality on MRI (3, 8%). Considering that the atypical and undercalled cases could have been adjusted in retrospect, and that 4 additional cases had positive lesions to the same extent and 11 further cases had disease confined to the pelvis, only 11 (4%) of the original 263 would have had disease outside of a conventional radiation treatment plan.
Conclusion: Notably, almost 50% of the cases, including most lymph node metastases, were anatomically normal using standard criteria. This suggests that current anatomic criteria for evaluating prostate cancer lymph node metastases are not ideal, and there is a need for improved criteria. In addition, 32% of cases involved some element of human interpretive error, and, therefore, improving reader training may lead to more accurate results.
References: Lancet. 2020 Apr 11;395(10231):1208-1216. (PMID: 32209449)
Curr Radiopharm. 2016;9(3):187-207. (PMID: 27804868)
J Urol. 2019 Apr;201(4):815-820. (PMID: 30672842)
Urology. 2008 Dec;72(6 Suppl):S25-35. (PMID: 19095125)
Mol Imaging Biol. 2020 Jun;22(3):788-796. (PMID: 31482413)
Transl Oncol. 2022 Jan;15(1):101242. (PMID: 34649151)
Front Oncol. 2021 May 04;11:633833. (PMID: 34017680)
Eur Radiol. 2019 Jun;29(6):3159-3169. (PMID: 30519933)
Cancer. 1995 Aug 15;76(4):661-8. (PMID: 8625162)
Med Sci Monit. 2020 Aug 27;26:e926544. (PMID: 32848125)
J Urol. 2011 Mar;185(3):869-75. (PMID: 21239008)
AJR Am J Roentgenol. 1996 Dec;167(6):1503-7. (PMID: 8956585)
J Nucl Med. 2020 Feb;61(2):194-201. (PMID: 31375566)
Radiol Imaging Cancer. 2023 Jan;5(1):e210115. (PMID: 36705559)
Sci Rep. 2023 May 23;13(1):8321. (PMID: 37221397)
Eur Urol. 2015 Jun;67(6):1009-1016. (PMID: 25308970)
Nat Rev Urol. 2016 Apr;13(4):226-35. (PMID: 26902337)
CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
Urology. 2005 Jun;65(6 Suppl):2-7. (PMID: 15939076)
Radiology. 2019 Feb;290(2):525-534. (PMID: 30480492)
J Urol. 2020 Mar;203(3):537-545. (PMID: 31487220)
World J Radiol. 2017 Oct 28;9(10):389-399. (PMID: 29104741)
Eur Radiol. 2020 Jul;30(7):3641-3649. (PMID: 32125513)
فهرسة مساهمة: Keywords: MRI; PET; PSMA; cancer; prostate; whole-body
تواريخ الأحداث: Date Created: 20240619 Latest Revision: 20240620
رمز التحديث: 20240620
مُعرف محوري في PubMed: PMC11171071
DOI: 10.3390/cancers16112056
PMID: 38893178
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers16112056